{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:48:11Z","timestamp":1793152091907,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ygyno.2020.05.013","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T07:15:02Z","timestamp":1590304502000},"page":"354-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG\/GOG 275"],"prefix":"10.1016","volume":"158","author":[{"given":"Julian C.","family":"Schink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Filiaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Q.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Moxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yabuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kushnir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.05.013_bb0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.05.013_bb0010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ygyno.2008.09.005","article-title":"Current management of gestational trophoblastic diseases","volume":"112","author":"Berkowitz","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajog.2010.06.072","article-title":"Classification and management of gestational trophoblastic neoplasia","volume":"204","author":"Lurain","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.05.013_bb0020","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ygyno.2012.03.003","article-title":"Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia","volume":"125","author":"Lybol","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"A phase III trial of weekly methotrexate or pulsed dactinomycin for low risk gestational trophoblastic neoplasia: a Gynecologic Oncolgy Group study","volume":"19","author":"Osborne","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF00422217","article-title":"Integrating health-related quality of life into cross-sectional clinical trials","volume":"2","author":"Cella","year":"1993","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0163278705275340","article-title":"Combining distributiion and anchor-based approaches to determining minimally important differences (the FACIT experience)","volume":"28","author":"Yost","year":"2005","journal-title":"Eval. Health Prof."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0002-9378(95)90575-8","article-title":"Single-agent methotrexate chemotherapy for treatment of nonmetastatic gestational trophoblastic tumors","volume":"172","author":"Lurain","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0090-8258(86)90123-X","article-title":"Ten year\u2019s experience with methtrexate and folinic acid as primary therapy for gestational trophoblastic disease","volume":"23","author":"Berkowitz","year":"1986","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0050","article-title":"First line chemotherapy in low-risk gestational trophoblastic neoplasia","volume":"10","author":"Lawrie","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2020.05.013_bb0055","series-title":"Chemotherapy for Gynecologic Cancers: Society of Gynecologic Oncology Handbook","first-page":"201","article-title":"Role of chemotherapy ion gestational trophoblastic disease","author":"Zsiros","year":"2017"},{"issue":"11","key":"10.1016\/j.ygyno.2020.05.013_bb0060","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1517\/14656566.4.11.2005","article-title":"Pharmacotherapy of gestational trophoblastic disease","volume":"4","author":"Lurain","year":"2003","journal-title":"Expert. Opin. Pharmacother."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820310817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820310817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:51:48Z","timestamp":1758772308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820310817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0090825820310817"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG\/GOG 275","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}